Study details
Enrolling now
Suvorexant Trial for Alcohol Use Disorder (AUD)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT IDNCT06484075ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
180
Study length
about 5.1 years
Ages
18–75
Locations
1 site in MD
What this study is about
This trial is testing if Suvorexant, a drug used to treat sleep problems, affects dopamine receptors in the brain of people with AUD and healthy volunteers. Participants will take either Suvorexant or a placebo for 1866 days while wearing a device that tracks their movements and having blood tests and brain scans.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Suvorexant
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
suvorexant
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health